Anlotinib Plus Irinotecan or Docetaxel Shows Promising Efficacy in SCLC

Article

Patients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress.

Patients with small cell lung cancer (SCLC) for whom first-line therapy failed within 6 months and who subsequently received treatment with anlotinib plus irinotecan or docetaxel showed antitumor activity and a manageable toxicity profile, according to data from a phase 2 study (NCT0457779).

The median progression-free survival was 4.0 months (95% CI, 3.16-4.84) and the median overall survival was 7.5 months (95% CI, 3.01-11.99) with the anlotinib combination. The overall response rate (ORR) in 21 patients was 47.6% and the disease control rate was 90.5%.

“Anlotinib plus irinotecan or docetaxel continued to show promising efficacy and manageable toxicities in SCLC relapsed within six months after first-line treatment. It may become a novel therapeutic strategy for the population,” Bing Xia, PhD, from Rutgers Cancer Institute, and colleagues wrote in a presentation of the data.

This single-arm study enrolled 26 participants, and 24 were eligible for the efficacy analysis. The median age was 61.9 years, with most (79.2%) being male and half (50%) being former. The median follow-up time was 8.4 months (95% CI, 2.58-14.22). At enrollment, 45.8% of patients (n = 11) had brain metastases and 41.7% (n = 10) had liver metastases.

Patients were eligible for this study if they were between the ages of 18 to 75 years, had cytologically or histologically confirmed SCLC, had relapsed within 6 months of receiving first-line treatment, and had an ECOG performance score of 0 to 1.

Patients were given 12 mg of anlotinib every day on day 1 to 14 of a 21-day cycle. For chemotherapy, patients were administered either irinotecan at 65 mg/m2 on days 1 and 8 once every 3 weeks for up to 4 cycles or docetaxel at 60 mg/m2 once every 3 weeks up to every 4 cycles.

The primary end point was ORR, with secondary end points of progression-free survival, disease control rate, overall survival, and safety.

A total of 21 patients were evaluable for responses, with 1 (4.76%) reaching a complete response, and 9 (42.86%) reaching a partial response.

The most reported all-grade treatment-related adverse effects were anemia (37.5%), weakness (37.5%), anorexia (33.3%), leukopenia (20.8%), and hypertension (20.8%). Patients also had grade 3 or higher adverse effects such as thrombocytopenia (8.4%), leukopenia (8.4%), and anemia (4.2%).

These data were previously made available in a poster at the 2021 European Society of Medical Oncology Congress.

Reference

Xia B, Chen X, Jiang H, et al. Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm phase II study. Ann Oncol. 2021;32(suppl 5):1657P. doi:10.1016/j.annonc.2021.08.241

Recent Videos
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
The use of novel agents like tarlatamab may be “interesting” among patients with small cell lung cancer in the relapsed setting, says Gregory Peter Kalemkerian, MD.
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.
Related Content